AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study

AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study

Hip Osteoarthritis (OA) causes pain and disability. Here we evaluate abobotulinumtoxinA (Dysport<sup>®</sup>) (AboBoNT-A) injections versus placebo as a novel treatment option to improve hip range of motion, pain and quality of life. This prospective randomized double-blind multicenter s...

Full description

Bibliographic Details
Main Authors: Roberto Eleopra, Sara Rinaldo, Christian Lettieri, Andrea Santamato, Paolo Bortolotti, Carmelo Lentino, Carmine Tamborino, Araldo Causero, Grazia Devigili
Format: Article
Language:English
Published: MDPI AG 2018-10-01
Series:Toxins
Subjects:
botulinum toxin
hip
osteoarthritis
rehabilitation
pain
Online Access:https://www.mdpi.com/2072-6651/10/11/448

Internet

https://www.mdpi.com/2072-6651/10/11/448

Similar Items